search
Back to results

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

Primary Purpose

X-Linked Retinitis Pigmentosa

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BIIB112
Sponsored by
NightstaRx Ltd, a Biogen Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for X-Linked Retinitis Pigmentosa focused on measuring XLRP, Ophthalmology, Gene Therapy, Retinitis Pigmentosa GTPase Regulator (RPGR), AAV8

Eligibility Criteria

10 Years - undefined (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

Key Inclusion Criteria:

Part 1:

  • Participants with genetically confirmed diagnosis of XLRP (with RPGR mutation).
  • Participant with active disease clinically visible within the macular region in both eyes.

Part 2:

- Participant with mean total retinal sensitivity in the study eye as assessed by microperimetry ≥ 0.1 dB and ≤8 dB.

Key exclusion Criteria:

Parts 1 and 2:

  • Participant with history of amblyopia in either eye.
  • Participated in a gene therapy trial previously or a clinical trial with an investigational drug in the past 12 weeks or received a gene/cell-based therapy at any time previously.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

No Intervention

Arm Label

Part 1: BIIB112 Dose 1

Part 1: BIIB112 Dose 2

Part 1: BIIB112 Dose 3

Part 1: BIIB112 Dose 4

Part 1: BIIB112 Dose 5

Part 1: BIIB112 Dose 6

Part 2: BIIB112 High Dose

Part 2: BIIB112 Low Dose

Part 2: Untreated Group

Arm Description

Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.

Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.

Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.

Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.

Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.

Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.

Participants will receive a single high dose of BIIB112 by sub-retinal injection.

Participants will receive a single low dose of BIIB112 by sub-retinal injection.

Participants will receive no intervention to allow for a controlled comparison.

Outcomes

Primary Outcome Measures

Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
DLTs are defined as any of the following events considered to be related to AAV8-RPGR: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within <24 hours} of the surgery); Vitreous inflammation, vitritis (>Grade 3 using standardised Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening.
Part 1: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Part 2: Percentage of Study Eyes with ≥7 Decibels (dB) Improvement from Baseline at ≥5 of the 16 Central Loci of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0', or a positive integer. The point labeled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points.
Part 2: Number of Participants with TEAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Secondary Outcome Measures

Parts 1 and 2 : Percentage of Study Eyes with ≥7 dB Improvement from Baseline at ≥5 out of the 16 Central Loci in Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points.
Parts 1 and 2: Percentage of Study Eyes with ≥7 dB Improvement from Baseline at ≥5 Out of the 68 Loci in Microperimetry
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points).
Parts 1 and 2: Change from Baseline in Mean Sensitivity of the 16 Central Loci
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points. Here negative values indicate a decline in retinal sensitivity.
Parts 1 and 2: Change from Baseline in Mean Sensitivity of the 68 Central Loci
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Parts 1 and 2: Change from Baseline in Best Corrected Visual Acuity (BCVA) Score
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Change from Baseline in Low Luminance Visual Acuity (LLVA) Score
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Increase from Baseline for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Increase from Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Increase from Baseline for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Increase from Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Increase from Baseline for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Increase from Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Loss from Baseline for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Loss from Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Loss from Baseline for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Loss from Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Loss from Baseline for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Loss from Baseline for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Parts 1 and 2: Percentage of Eyes with Change from Baseline > -5 Letters for BCVA
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Part 1 and 2: Percentage of Eyes with Change from Baseline > -5 Letters for LLVA
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Part 1: Change from Baseline in Central Ellipsoid Area
Spectral Domain Optical Coherence Tomography (SD-OCT) was used to assess change in central ellipsoid area.
Part 1: Change from Baseline in Central Horizontal Ellipsoid Width
SD-OCT was used to assess change in central horizontal ellipsoid width. Here negative values indicate decline in central horizontal ellipsoid width.
Part 1: Change from Baseline in Fundus Autofluorescence- Total Area of Preserved Autofluoroscence
Fundus Autofluorescence was used to assess change in total area of preserved autofluorescence and distance from foveal center (FC) to nearest border of preserved autofluorescence.
Part 1: Change from Baseline in Fundus Autofluorescence- Distance from Foveal Center (FC) to Nearest Border of Preserved Autofluorescence
Fundus Autofluorescence was used to assess change in distance from foveal center (FC) to nearest border of preserved autofluorescence.
Part 1: Change from Baseline in Volume of 30-Degree Hill of Vision
Visual field testing was performed to assess change in volume of 30-degree hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable.
Part 1: Change from Baseline in Volume of Full Field Hill of Vision
Visual field testing was performed to assess change in volume of full field hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable.
Part 1: Change from Baseline in Contrast Sensitivity
Change in contrast sensitivity (CS) was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters. Chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Subjects read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. Each group has three letters of the same contrast level, so there are three trials per contrast level. Subject is assigned a score based on the contrast of the last group in which two or three letters were correctly read. Score is a measure of the subject's log contrast sensitivity ranging from 0-2.25, with 0 being no letters read, and 2.25 being all letters read. Total CS score = [(total # letters correct - 3) x 0.05].
Part 2: Change from Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Visual field testing was performed to assess change in volume of 30-degree hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Here negative values indicate decline in the volume of 30-degree hill vision.
Part 2: Change from Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Visual field testing was performed to assess change in volume of full field hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Here negative values indicate decline in volume of full field hill vision.

Full Information

First Posted
March 29, 2017
Last Updated
February 9, 2023
Sponsor
NightstaRx Ltd, a Biogen Company
search

1. Study Identification

Unique Protocol Identification Number
NCT03116113
Brief Title
A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
Acronym
XIRIUS
Official Title
A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
March 16, 2017 (Actual)
Primary Completion Date
November 18, 2020 (Actual)
Study Completion Date
November 18, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NightstaRx Ltd, a Biogen Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of the study is to evaluate the safety, tolerability and efficacy of a single sub-retinal injection of BIIB112 in participants with X-linked retinitis pigmentosa (XLRP).
Detailed Description
This study was previously posted by NightstaRx Ltd. In October, 2020, sponsorship of the trial was transferred to Biogen.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
X-Linked Retinitis Pigmentosa
Keywords
XLRP, Ophthalmology, Gene Therapy, Retinitis Pigmentosa GTPase Regulator (RPGR), AAV8

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part 1: BIIB112 Dose 1
Arm Type
Experimental
Arm Description
Participants will receive a single Dose 1 of BIIB112 by sub-retinal injection on Day 0.
Arm Title
Part 1: BIIB112 Dose 2
Arm Type
Experimental
Arm Description
Participants will receive a single Dose 2 of BIIB112 by sub-retinal injection on Day 0.
Arm Title
Part 1: BIIB112 Dose 3
Arm Type
Experimental
Arm Description
Participants will receive a single Dose 3 of BIIB112 by sub-retinal injection on Day 0.
Arm Title
Part 1: BIIB112 Dose 4
Arm Type
Experimental
Arm Description
Participants will receive a single Dose 4 of BIIB112 by sub-retinal injection on Day 0.
Arm Title
Part 1: BIIB112 Dose 5
Arm Type
Experimental
Arm Description
Participants will receive a single Dose 5 of BIIB112 by sub-retinal injection on Day 0.
Arm Title
Part 1: BIIB112 Dose 6
Arm Type
Experimental
Arm Description
Participants will receive a single Dose 6 of BIIB112 by sub-retinal injection on Day 0.
Arm Title
Part 2: BIIB112 High Dose
Arm Type
Experimental
Arm Description
Participants will receive a single high dose of BIIB112 by sub-retinal injection.
Arm Title
Part 2: BIIB112 Low Dose
Arm Type
Experimental
Arm Description
Participants will receive a single low dose of BIIB112 by sub-retinal injection.
Arm Title
Part 2: Untreated Group
Arm Type
No Intervention
Arm Description
Participants will receive no intervention to allow for a controlled comparison.
Intervention Type
Biological
Intervention Name(s)
BIIB112
Other Intervention Name(s)
AAV8-RPGR
Intervention Description
Administered as specified in the treatment arm
Primary Outcome Measure Information:
Title
Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
Description
DLTs are defined as any of the following events considered to be related to AAV8-RPGR: Sustained decrease in best-corrected visual acuity (BCVA) of ≥30 letters on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart compared to baseline (sustained is defined as lasting 48 hours or more until recovery, with recovery defined as visual acuity (VA) returning to within 10 letters of baseline VA. An exception is made for surgery-related events occurring in close temporal association {within <24 hours} of the surgery); Vitreous inflammation, vitritis (>Grade 3 using standardised Nussenblatt vitreous inflammation scale grading); Any clinically significant retinal damage observed that is not directly attributed to complications of surgery; Any clinically relevant suspected unexpected serious adverse reaction, with the exception of vision loss or vision threatening.
Time Frame
Up to Month 24
Title
Part 1: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Description
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time Frame
Up to Month 24
Title
Part 2: Percentage of Study Eyes with ≥7 Decibels (dB) Improvement from Baseline at ≥5 of the 16 Central Loci of the 10-2 Grid Assessed by Macular Integrity Assessment (MAIA) Microperimetry
Description
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0', or a positive integer. The point labeled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points.
Time Frame
Months 12
Title
Part 2: Number of Participants with TEAEs
Description
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time Frame
Up to Month 12
Secondary Outcome Measure Information:
Title
Parts 1 and 2 : Percentage of Study Eyes with ≥7 dB Improvement from Baseline at ≥5 out of the 16 Central Loci in Microperimetry
Description
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18 and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Study Eyes with ≥7 dB Improvement from Baseline at ≥5 Out of the 68 Loci in Microperimetry
Description
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' was assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points).
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18 and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Change from Baseline in Mean Sensitivity of the 16 Central Loci
Description
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in center grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points out of the 16 central points. Here negative values indicate a decline in retinal sensitivity.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18 and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Change from Baseline in Mean Sensitivity of the 68 Central Loci
Description
MAIA microperimetry assessment was measured in dB using a 10-2 grid of 68 points. Each point was labeled as '< 0', '0' or a positive integer. The point labeled as '< 0' is assigned a value of '-1' by MAIA in the calculation. Improvement in Retinal Sensitivity in whole grid was defined as an increase from baseline of 7 or more decibels in any 5 or more points of the grid as a whole (68 points). Here negative values indicate a decline in retinal sensitivity.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18 and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Change from Baseline in Best Corrected Visual Acuity (BCVA) Score
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18 and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Change from Baseline in Low Luminance Visual Acuity (LLVA) Score
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Increase from Baseline for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Increase from Baseline for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Increase from Baseline for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Increase from Baseline for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Increase from Baseline for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Increase from Baseline for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Loss from Baseline for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥15 Letters Loss from Baseline for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Loss from Baseline for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥10 Letters Loss from Baseline for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Loss from Baseline for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with a ≥5 Letters Loss from Baseline for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Parts 1 and 2: Percentage of Eyes with Change from Baseline > -5 Letters for BCVA
Description
BCVA was assessed using the ETDRS VA chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. BCVA was to be reported as number of letters read correctly by the subject. An increase in the number of letters read correctly means that vision has improved.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 2, 3, 6, 9, and 12
Title
Part 1 and 2: Percentage of Eyes with Change from Baseline > -5 Letters for LLVA
Description
LLVA was measured by placing a 2.0-log-unit neutral density filter over the front of each eye and having the subject read the normally illuminated ETDRS chart. Initially, letters were read at a distance of 4 meters from the chart. If <20 letters were read at 4 meters, testing at 1 meter was performed. LLVA was reported as number of letters read correctly by the subject.
Time Frame
Part 1: Month 1, 3, 6, 9, 12, 18, and 24; Part 2: Month 1, 3, 6, 9, and 12
Title
Part 1: Change from Baseline in Central Ellipsoid Area
Description
Spectral Domain Optical Coherence Tomography (SD-OCT) was used to assess change in central ellipsoid area.
Time Frame
Month 1, 3, 6, 9, 12, 18 and 24
Title
Part 1: Change from Baseline in Central Horizontal Ellipsoid Width
Description
SD-OCT was used to assess change in central horizontal ellipsoid width. Here negative values indicate decline in central horizontal ellipsoid width.
Time Frame
Month 1, 3, 6, 9, 12, 18 and 24
Title
Part 1: Change from Baseline in Fundus Autofluorescence- Total Area of Preserved Autofluoroscence
Description
Fundus Autofluorescence was used to assess change in total area of preserved autofluorescence and distance from foveal center (FC) to nearest border of preserved autofluorescence.
Time Frame
Month 1, 3, 6, 12, 18 and 24
Title
Part 1: Change from Baseline in Fundus Autofluorescence- Distance from Foveal Center (FC) to Nearest Border of Preserved Autofluorescence
Description
Fundus Autofluorescence was used to assess change in distance from foveal center (FC) to nearest border of preserved autofluorescence.
Time Frame
Month 1, 3, 6, 9, 12, 18 and 24
Title
Part 1: Change from Baseline in Volume of 30-Degree Hill of Vision
Description
Visual field testing was performed to assess change in volume of 30-degree hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable.
Time Frame
Month 6, 12 and 24
Title
Part 1: Change from Baseline in Volume of Full Field Hill of Vision
Description
Visual field testing was performed to assess change in volume of full field hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable.
Time Frame
Month 6, 12, and 24
Title
Part 1: Change from Baseline in Contrast Sensitivity
Description
Change in contrast sensitivity (CS) was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters. Chart uses letters (6 per line), arranged in groups whose contrast varies from high to low. Subjects read the letters, starting with the highest contrast, until they are unable to read two or three letters in a single group. Each group has three letters of the same contrast level, so there are three trials per contrast level. Subject is assigned a score based on the contrast of the last group in which two or three letters were correctly read. Score is a measure of the subject's log contrast sensitivity ranging from 0-2.25, with 0 being no letters read, and 2.25 being all letters read. Total CS score = [(total # letters correct - 3) x 0.05].
Time Frame
Month 3, 6, 12 and 24
Title
Part 2: Change from Baseline in Volume of 30-Degree Hill of Vision Assessed by Octopus 900
Description
Visual field testing was performed to assess change in volume of 30-degree hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Here negative values indicate decline in the volume of 30-degree hill vision.
Time Frame
Baseline, Month 3, 6 and 12
Title
Part 2: Change from Baseline in Volume of Full Field Hill of Vision Assessed by Octopus 900
Description
Visual field testing was performed to assess change in volume of full field hill vision. Reliability Factor (RF)=number of false positive responses + number of false negative responses/number of false positive presentations + number of false negative presentations*100. If there are 0 responses, then RF value=0. RFpositive=number of false positive responses/number of false positive presentations*100. If RF≤ 20% measurement is considered reliable. If 20% < RF ≤ 25% and RFpositive ≤ 10% measurement is also considered reliable. Otherwise if 20% < RF ≤ 25% and RFpositive > 10%, or RF > 25%, measurement is not reliable. Here negative values indicate decline in volume of full field hill vision.
Time Frame
Baseline, Month 3, 6 and 12

10. Eligibility

Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Part 1: Participants with genetically confirmed diagnosis of XLRP (with RPGR mutation). Participant with active disease clinically visible within the macular region in both eyes. Part 2: - Participant with mean total retinal sensitivity in the study eye as assessed by microperimetry ≥ 0.1 dB and ≤8 dB. Key exclusion Criteria: Parts 1 and 2: Participant with history of amblyopia in either eye. Participated in a gene therapy trial previously or a clinical trial with an investigational drug in the past 12 weeks or received a gene/cell-based therapy at any time previously. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Biogen
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32607
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Research Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Research Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Research Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Research Site
City
Manchester
Country
United Kingdom
Facility Name
Research Site
City
Oxford
Country
United Kingdom
Facility Name
Research Site
City
Southampton
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/
IPD Sharing URL
https://vivli.org/
Citations:
PubMed Identifier
32094925
Citation
Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, Davies A, Wood LJ, Salvetti AP, Fischer MD, Aylward JW, Barnard AR, Jolly JK, Luo E, Lujan BJ, Ong T, Girach A, Black GCM, Gregori NZ, Davis JL, Rosa PR, Lotery AJ, Lam BL, Stanga PE, MacLaren RE. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020 Mar;26(3):354-359. doi: 10.1038/s41591-020-0763-1. Epub 2020 Feb 24.
Results Reference
derived

Learn more about this trial

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

We'll reach out to this number within 24 hrs